Lung Disease
Conditions
Keywords
Ketamine, Alfentanil, Propofol, Oxygen saturation, Percutaneous carbon dioxide, Bronchoscopy
Brief summary
A prospective, randomized, patient-blinded comparison of the safety and efficacy of conscious sedation by propofol/alfentanil with propofol/ketamine in patients undergoing flexible fiberoptic bronchoscopy.
Detailed description
The study group will include 80 patients undergoing flexible fiberoptic bronchoscopy(FFB). Patients will be randomly assigned prior to the procedure to receive sedation by either propofol/alfentanil (PA group) or propofol/ketamine (PK group), using either the sealed envelope method or by computer randomization. All patients will receive local anesthesia with Lidocaine 2% (total dose of 5-10 ml) that will be sprayed via the bronchoscope on the vocal cords before passage through them, as well as into the bronchial tree in order to suppress coughing. In addition, patients from both groups will optionally receive intravenous Midazolam (up to a total dose of 0.05 mg/kg)if deemed necessary during the procedure. Sedation will be started by 10-15 mcg/kg Alfentanil and 0.4 mg/kg Propofol, or by 0.2-0.3 mg/kg Ketamine and 0.4 mg/kg Propofol. It will be maintained by additional boluses of Propofol (aliquots of 10-50 mg) or by additional boluses of Propofol (aliquots of 10-50 mg) and/or Ketamine (aliquots of 5-25 mg). All patients will receive supplemental oxygen via nasal cannula (2-4 L/min) before the beginning of the procedure. Patients whose functional oxygen saturation (SpO2) prior to the beginning of the procedure will be lower than 92% while connected to a nasal cannula, will receive oxygen supplementation via a face mask. If the SpO2 after initiation of sedation will fall below 90%, the patients' airways will be opened using a jaw-thrust maneuver or insertion of a nasal airway. Should the SpO2 remain low, the patient will receive oxygen supplementation via a face-mask. If deemed necessary, additional safety measures will be taken by the anesthesiologist or by the performer of the bronchoscopy, such as administration of oxygen directly through the bronchoscope, assisted ventilation with an Ambu bag, and tracheal intubation. The duration of bronchoscopy will be calculated from the administration of sedation until the flexible bronchoscope is removed from the tracheobronchial tree. In all cases, patients will be monitored using continuous electrocardiography, pulse oximetry, and transcutaneous carbon dioxide (PtCO2, using a digital sensor placed on the patient's earlobe),and automated noninvasive blood pressure recordings every 5 minutes. All parameters will be recorded beginning from prior to connecting the patient to the nasal cannula before initiation of sedation, throughout the entire procedure and until 10 minutes after removal of the bronchoscope from the nasopharynx. Immediately after the end of the procedure, the bronchoscopist will grade the quality of sedation (ease of performing the procedure) by Visual Analog Scale. A questionnaire evaluating pain and discomfort by Visual Analog Scale will be completed by the patient when fully awake after the procedure.(\ 30 minutes after the end of the procedure). Percutaneous carbon dioxide tension, blood oxygenation, heart rate, and blood pressure will be compared between the groups.
Interventions
DRUGPropofol
DRUGKetamine
DRUGAlfentanil
Sponsors
Rabin Medical Center
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* American Society of Anesthesiologists grade I or II * patients that will be referred to the procedure for bronchoalveolar lavage and cytologic/bacteriologic sampling, endoluminal biopsies for pathologic /bacteriologic analysis, or for regaining patency (mechanically or laser-assisted) of airways that are obstructed by secretions, tumors or foreign bodies
Exclusion criteria
* patient refusal or inability to provide informed consent * American Society of Anesthesiologists grade III or higher * allergy to study medications * patients who have an endotracheal tube or tracheostomy
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Percutaneous carbon dioxide tension | Average expected time of 45 minutes | Continuous measurements (record every 4 seconds). Throughout the duration of fiberoptic bronchoscopy - from the beginning of the procedure until 10 minutes after its termination. |
| oxygen saturation | Average expected time of 45 minutes. | Continuous measurements (record every 4 seconds). Throughout the duration of fiberoptic bronchoscopy - from the beginning of the procedure until 10 minutes after its termination. |
| heart rate | Average expected time of 45 minutes | Continuous measurements (record every 4 seconds). Throughout the duration of fiberoptic bronchoscopy - from the beginning of the procedure until 10 minutes after its termination. |
| Non-invasive blood pressure | Average expected time of 45 minutes | Every 5 minutes. Throughout the duration of fiberoptic bronchoscopy - from the beginning of the procedure until 10 minutes after its termination |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Total propofol dosage | Average expected time of 30 minutes | The total amount of propofol used throughout the procedure will be calculated. |
| Oxygen supplementation | Average expected time of 45 minutes | Significant hypoxemia, defined as functional SpO2 of 90%, will be treated initially with a jaw thrust maneuver. If it lasts more than few seconds, a naso/oropharyngeal tube will be inserted or supplemental oxygen will be delivered via face mask at 10 L min-1. The percentage of patients who needed supplemental oxygen will be evaluated |
| Time to discharge | Average expected time of 60 minutes. Anticipated to be in the range of 45-120 minutes after the end of fiberoptic bronchoscopy | The time from the termination of the procedure until the patient is discharged from the recovery unit will be measured. |
| Time to full awakening and orientation | Anticipated to be in the range of 1-30 minutes after the end of the procedure | Time from termination of the procedure to full awakening and orientation |
| Naso/oropharyngeal tube insertion | Average expected time of 45 minutes | Significant hypoxemia, defined as functional SpO2 of 90%, will be treated initially with jaw support. If it lasts more than few seconds, a naso/oropharyngeal tube will be inserted or supplemental oxygen will be delivered via face mask at 10 L min-1 The percentage of patients who needed Naso/oropharyngeal tube insertion will be evaluated |
| A questionnaire evaluating pain and discomfort | Ca. 30 minutes after the end of the procedure (average expected time of 60 minutes) | A questionnaire evaluating pain and discomfort by Visual Analog Scale will be completed by the patient when awake after the procedure.(\ 30 minutes after the end of the procedure) |
| A questionnaire evaluating the quality of sedation | Immediately after end of procedure (average expected time of 30 minutes) | A questionnaire evaluating the quality of sedation and the ease of performing the procedure by Visual Analog Scale will be completed by the bronchoscopist immediately after the procedure. |
Countries
Israel
Contacts
Primary ContactYair Manevich, MD
Outcome results
None listed